• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

全面的泛癌分析确定FHL2与肺腺癌的不良预后相关。

Comprehensive pan-cancer analysis identifies FHL2 associated with poor prognosis in lung adenocarcinoma.

作者信息

Pan Bin, Wan Li, Li Yu, Yang Jian, Chen Zhike, Tong Xin, Zhao Jun, Li Chang

机构信息

Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.

Institute of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

Transl Cancer Res. 2023 Jun 30;12(6):1516-1534. doi: 10.21037/tcr-22-2786. Epub 2023 Jun 20.

DOI:10.21037/tcr-22-2786
PMID:37434686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10331713/
Abstract

BACKGROUND

The FHL family (four-and-a-half-LIM-only protein family) contains five multifunctional proteins (FHL1-5) that are involved in cell survival, transcriptional regulation, and signal transduction. Among these proteins, FHL2 is one of the most reported members in tumors, which is differentially expressed in numerous tumors. However, no systematic pan-cancer analysis of FHL2 has been performed so far.

METHODS

We obtained The Cancer Genome Atlas (TCGA) expression profiles and clinical data from Xena database and the Tumor Immune Estimation Resource (TIMER) database. Gene expression, prognosis, mRNA modification, and immune infiltration of FHL2 in pan-cancer were analyzed. Functional analysis validated the potential mechanism of FHL2 in lung adenocarcinoma (LUAD).

RESULTS

FHL2 is differentially expressed in a wide range of tumors and has prognostic value. Digging into the immune landscape of FHL2, we found that FHL2 is significantly associated with tumor-associated fibroblasts. Furthermore, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) suggested that FHL2 may be involved in epithelial-mesenchymal transition (EMT)-associated pathways such as NF-KB and TGF-β in LUAD.

CONCLUSIONS

Our comprehensive bioinformatics analysis identified mRNA level expression of FHL2 correlates with prognosis in different cancers. This study may help to more fully explore the role of FHL2 in tumor progression and metastasis.

摘要

背景

FHL家族（仅含四个半LIM结构域蛋白家族）包含五种多功能蛋白（FHL1 - 5），它们参与细胞存活、转录调控和信号转导。在这些蛋白中，FHL2是肿瘤中报道最多的成员之一，在众多肿瘤中差异表达。然而，迄今为止尚未对FHL2进行系统的泛癌分析。

方法

我们从Xena数据库和肿瘤免疫评估资源（TIMER）数据库获取了癌症基因组图谱（TCGA）的表达谱和临床数据。分析了FHL2在泛癌中的基因表达、预后、mRNA修饰和免疫浸润情况。功能分析验证了FHL2在肺腺癌（LUAD）中的潜在机制。

结果

FHL2在多种肿瘤中差异表达且具有预后价值。深入研究FHL2的免疫格局，我们发现FHL2与肿瘤相关成纤维细胞显著相关。此外，基因本体论（GO）、京都基因与基因组百科全书（KEGG）和基因集富集分析（GSEA）表明，FHL2可能参与LUAD中与上皮-间质转化（EMT）相关的途径，如NF-κB和TGF-β途径。

结论

我们全面的生物信息学分析确定FHL2的mRNA水平表达与不同癌症的预后相关。本研究可能有助于更全面地探索FHL2在肿瘤进展和转移中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/b9198ca4ebac/tcr-12-06-1516-f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/bc586ecfd23b/tcr-12-06-1516-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/7b2e38b59f11/tcr-12-06-1516-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/731e2aa75d38/tcr-12-06-1516-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/81e938ff90cb/tcr-12-06-1516-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/1335486b3bc4/tcr-12-06-1516-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/96f9339ad1a3/tcr-12-06-1516-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/df00a09be91f/tcr-12-06-1516-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/d18500b89965/tcr-12-06-1516-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/62712337adb2/tcr-12-06-1516-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/6d3f9a9ebe1e/tcr-12-06-1516-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/b9198ca4ebac/tcr-12-06-1516-f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/bc586ecfd23b/tcr-12-06-1516-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/7b2e38b59f11/tcr-12-06-1516-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/731e2aa75d38/tcr-12-06-1516-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/81e938ff90cb/tcr-12-06-1516-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/1335486b3bc4/tcr-12-06-1516-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/96f9339ad1a3/tcr-12-06-1516-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/df00a09be91f/tcr-12-06-1516-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/d18500b89965/tcr-12-06-1516-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/62712337adb2/tcr-12-06-1516-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/6d3f9a9ebe1e/tcr-12-06-1516-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4126/10331713/b9198ca4ebac/tcr-12-06-1516-f11.jpg

相似文献

1
Comprehensive pan-cancer analysis identifies FHL2 associated with poor prognosis in lung adenocarcinoma.全面的泛癌分析确定FHL2与肺腺癌的不良预后相关。
Transl Cancer Res. 2023 Jun 30;12(6):1516-1534. doi: 10.21037/tcr-22-2786. Epub 2023 Jun 20.
2
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.鉴定SHCBP1作为一种潜在的生物标志物，涉及多种癌症的诊断、预后及肿瘤免疫微环境。
Comput Struct Biotechnol J. 2022 Jun 18;20:3106-3119. doi: 10.1016/j.csbj.2022.06.039. eCollection 2022.
3
Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.半胱氨酸蛋白酶抑制剂 SN 促进肺腺癌的上皮间质转化并作为预后生物标志物。
BMC Cancer. 2022 May 30;22(1):589. doi: 10.1186/s12885-022-09685-z.
4
Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.构建肺腺癌的预后免疫相关长链非编码RNA风险模型
Front Cell Dev Biol. 2021 Mar 18;9:648806. doi: 10.3389/fcell.2021.648806. eCollection 2021.
5
Evaluation of the Prognostic Value of STEAP1 in Lung Adenocarcinoma and Insights Into Its Potential Molecular Pathways via Bioinformatic Analysis.通过生物信息学分析评估STEAP1在肺腺癌中的预后价值及其潜在分子途径
Front Genet. 2020 Mar 20;11:242. doi: 10.3389/fgene.2020.00242. eCollection 2020.
6
Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.综合分析与验证揭示ACAP1是一种与肺腺癌肿瘤免疫相关的新型预后生物标志物。
Comput Struct Biotechnol J. 2022 Aug 13;20:4390-4401. doi: 10.1016/j.csbj.2022.08.026. eCollection 2022.
7
Comprehensive analysis to identify a novel diagnostic marker of lung adenocarcinoma and its immune infiltration landscape.综合分析以鉴定肺腺癌的一种新型诊断标志物及其免疫浸润图谱。
Front Oncol. 2023 Jun 20;13:1199608. doi: 10.3389/fonc.2023.1199608. eCollection 2023.
8
AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.AUNIP表达与免疫浸润相关，是肝细胞癌和肺腺癌的候选诊断及预后生物标志物。
Front Oncol. 2020 Dec 9;10:590006. doi: 10.3389/fonc.2020.590006. eCollection 2020.
9
Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.泛癌综合分析鉴定出SASH3，一种抑制肺腺癌进展的潜在生物标志物。
Front Oncol. 2022 Jun 3;12:927988. doi: 10.3389/fonc.2022.927988. eCollection 2022.
10
A new prognostic model for , , and to predict the prognosis and association with immune infiltration of lung adenocarcinoma.一种用于预测肺腺癌预后以及与免疫浸润相关性的、针对[具体内容缺失]的新预后模型。
J Thorac Dis. 2023 Apr 28;15(4):1919-1934. doi: 10.21037/jtd-23-265. Epub 2023 Apr 10.

引用本文的文献

1
Ten-Year Observational Study of Patients with Lung Adenocarcinoma: Clinical Outcomes, Prognostic Factors, and Five-Year Survival Rates.肺腺癌患者的十年观察性研究：临床结果、预后因素及五年生存率
J Clin Med. 2025 Apr 8;14(8):2552. doi: 10.3390/jcm14082552.
2
A novel tumor-derived exosomal gene signature predicts prognosis in patients with pancreatic cancer.一种新型肿瘤衍生外泌体基因特征可预测胰腺癌患者的预后。
Transl Cancer Res. 2024 Aug 31;13(8):4324-4340. doi: 10.21037/tcr-23-2354. Epub 2024 Aug 26.
3
Promotion of non-small cell lung cancer tumor growth by via inducing angiogenesis and vascular permeability.

本文引用的文献

1
Development and validation of a novel ubiquitination-related gene prognostic signature based on tumor microenvironment for colon cancer.基于肿瘤微环境的结肠癌新型泛素化相关基因预后特征的开发与验证
Transl Cancer Res. 2022 Oct;11(10):3724-3740. doi: 10.21037/tcr-22-607.
2
High level of FHL2 exacerbates the outcome of non-small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells.FHL2 高表达加剧了非小细胞肺癌（NSCLC）患者的预后不良和 NSCLC 细胞的恶性表型。
Int J Exp Pathol. 2022 Jun;103(3):90-101. doi: 10.1111/iep.12436. Epub 2022 Apr 2.
3
Cancer statistics, 2022.
通过诱导血管生成和血管通透性促进非小细胞肺癌肿瘤生长。 （你提供的原文“by via”表述有误，推测原文可能是“by via”，这里按照修正后的理解进行了翻译。）
J Thorac Dis. 2024 Feb 29;16(2):1424-1437. doi: 10.21037/jtd-23-1975. Epub 2024 Feb 23.
癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
4
IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures.IOBR：多组学免疫肿瘤生物学研究解码肿瘤微环境和特征。
Front Immunol. 2021 Jul 2;12:687975. doi: 10.3389/fimmu.2021.687975. eCollection 2021.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.
7
Role of RNA modifications in cancer.RNA 修饰在癌症中的作用。
Nat Rev Cancer. 2020 Jun;20(6):303-322. doi: 10.1038/s41568-020-0253-2. Epub 2020 Apr 16.
8
mRNA modification orchestrates cancer stem cell fate decisions.信使核糖核酸修饰调控癌症干细胞的命运决定。
Mol Cancer. 2020 Feb 26;19(1):38. doi: 10.1186/s12943-020-01166-w.
9
Up-regulated FHL2 inhibits ovulation through interacting with androgen receptor and ERK1/2 in polycystic ovary syndrome.上调的 FHL2 通过与雄激素受体和 ERK1/2 相互作用抑制多囊卵巢综合征中的排卵。
EBioMedicine. 2020 Feb;52:102635. doi: 10.1016/j.ebiom.2020.102635. Epub 2020 Feb 3.
10
A framework for advancing our understanding of cancer-associated fibroblasts.推进我们对癌症相关成纤维细胞理解的框架。
Nat Rev Cancer. 2020 Mar;20(3):174-186. doi: 10.1038/s41568-019-0238-1. Epub 2020 Jan 24.